对比分析缬沙坦胶囊与奥美沙坦酯片治疗高血压病早期肾损伤的疗效及对24 h-UTP、24 h-ALB的影响  

Efficacy of valsartan and olmesartan medoxomil in the treatment of early renal injury in hypertension and effects on 24 h-UTP and 24 h-ALB

作　　者：万林辉 叶俏霞 郑涤凡 龚勋 高雅 WAN Lin-hui;YE Qiao-xia;ZHENG Di-fan(Department of Pharmacy,Huizhou Central People's Hospital,Huizhou Guangzhou 516000,China.)

机构地区：[1]惠州市中心人民医院药学部,广东惠州516000

出　　处：《临床和实验医学杂志》2022年第19期2051-2054,共4页Journal of Clinical and Experimental Medicine

基　　金：广东省医疗卫生类科技计划项目(编号:2019Y116)。

摘　　要：目的分析缬沙坦胶囊与奥美沙坦酯片治疗高血压病早期肾损伤的疗效及对24 h尿总蛋白(24 h-UTP)、24 h微量清蛋白(24 h-ALB)的影响,为临床选择最佳用药提供可靠数据。方法前瞻性选取2019年1月到2020年12月在惠州市中心人民医院诊治的高血压病早期肾损伤患者102例。采用随机数字表法将其分成对照组和研究组,例数均是51例。对照组患者接受缬沙坦胶囊治疗,研究组患者接受奥美沙坦酯片治疗。比较两组患者临床疗效、清晨24 h-UTP、24 h-ALB水平、凝血功能指标[纤维蛋白原(Fg)、D-二聚体]和不良反应发生情况。结果研究组患者临床总有效率为98.04%,高于对照组(80.39%),差异有统计学意义(P<0.05)。治疗前,研究组患者清晨24 h-UTP、24 h-ALB水平与对照组比较,差异无统计学意义(P>0.05);治疗后,研究组患者清晨24 h-UTP、24 h-ALB水平分别为(16.36±2.01)、(30.58±3.58)mg/L,均低于对照组[(26.58±2.07)、(41.69±3.51)mg/L],差异均有统计学意义(P<0.05)。治疗前,研究组患者Fg、D-二聚体水平与对照组比较,差异无统计学意义(P>0.05);治疗后,研究组患者Fg、D-二聚体水平为(2.01±0.11)g/L、(1.48±0.22)mg/L,均低于对照组[(2.54±0.17)g/L、(1.87±0.24)mg/L],差异均有统计学意义(P<0.05)。研究组不良反应发生率为5.88%,低于对照组(9.80%),但差异无统计学意义(P>0.05)。结论奥美沙坦酯片较缬沙坦胶囊在治疗高血压病早期肾损伤能提升临床疗效,改善肾功能和凝血功能,且安全性较好,建议使用。Objective To analyze the efficacy of valsartan and olmesartan medoxomil in the treatment of early renal injury in hypertension,and to assess the effects on 24-hour urine total protein(24 h-UTP)and 24-hour albumin(24 h-ALB),so as to provide reliable basis for clinical treatment.Methods A total of 102 hypertension patients with early renal injury in Huizhou Central People's Hospital from January 2019 to December 2020 were prospectively selected,and divided into two groups according to the random number table method,each with 51 cases.Control group received valsartan treatment,while study group received olmesartan medoxomil treatment,then various indexes were compared between the two groups,including clinical efficacy,fasting levels of 24 h-UTP and 24 h-ALB,coagulation function indicators[fibrinogen(Fg),D-dimer]and adverse effects.Results The clinical efficacy in study group was 98.04%,which was significantly higher than that in control group(80.39%),the difference was statistically significant(P<0.05).Before treatment,the levels of 24 h-UTP and 24 h-ALB in the study group in the morning were not significantly different from those in the control group(P>0.05);the levels of 24 h-UTP and 24 h-ALB in the study group in the morning after treatment were(16.36±2.01)and(30.58±3.58)mg/L,which were lower than those in the control group[(26.58±2.07),(41.69±3.51)mg/L],the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in the levels of Fg and D-dimer between the study group and the control group(P>0.05);the levels of Fg and D-dimer in the study group after treatment were(2.01±0.11)g/L,(1.48±0.22)mg/L,which were lower than those in the control group[(2.54±0.17)g/L,(1.87±0.24)mg/L],the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the study group was 5.88%,which was lower than that in the control group(9.80%),but the difference was not statistically significant(P>0.05).Conclusion Compared with valsartan treatment,appl

关 键 词：高血压病 早期肾损伤 缬沙坦胶囊 奥美沙坦酯片 24 h尿总蛋白 24 h微量清蛋白 

分 类 号：R544.1[医药卫生—心血管疾病] R692[医药卫生—内科学]